6-TGN levels (azathioprine drug monitoring) and markers of mucosal healing in patients with inflammatory bowel disease

• Conditions: K50; K51; Crohn disease [regional enteritis]; Ulcerative colitis

• Registration Number: DRKS00013246
• Lead Sponsor: MHH OE6810

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-21
• Study Completion: 2018-02-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

IBD, azathioprine Therapy, values for 6-TGN and FC (max. 4 weeks apart), patients from 2009-2016

Exclusion Criteria

Steroids >20 mg, additional immunosuppressive therapy during last 3 months or currently

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between 6-TGN (6-Thioguanin-Nucleotide) and fecal calprotectin; retrospective data analysis

Secondary Outcome Measures

Name	Time	Method
Subgroup analysis of patients in clinical remission